Thromb Haemost 2023; 123(12): 1177-1179
DOI: 10.1055/a-2152-4762
Invited Editorial Focus

Kidney Disease and Cancer Risk in Patients with Venous Thromboembolism: What Does It Mean for Clinical Practice?

1   Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
2   Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece
› Author Affiliations




Publication History

Accepted Manuscript online:
11 August 2023

Article published online:
18 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Dentali F, Ageno W, Pomero F, Fenoglio L, Squizzato A, Bonzini M. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb Haemost 2016; 115 (02) 399-405
  • 2 Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE. European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 2016; 115 (04) 800-808
  • 3 Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost 2011; 106 (03) 405-415
  • 4 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
  • 5 Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2017; 15 (10) 2076-2079
  • 6 Rønnow Sand J, Troelsen FS, Nagy D. et al. Increased cancer risk in patients with kidney disease and venous thromboembolism: a population-based cohort study. Thromb Haemost 2023; 123 (12) 1165-1176
  • 7 Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. [see comments] N Engl J Med 1998; 338 (17) 1169-1173
  • 8 Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351 (9109) 1077-1080
  • 9 Prandoni P, Lensing AW, Büller HR. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327 (16) 1128-1133
  • 10 Carrier M, Lazo-Langner A, Shivakumar S. et al; SOME Investigators. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med 2015; 373 (08) 697-704
  • 11 Robin P, Le Roux PY, Planquette B. et al; MVTEP study group. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol 2016; 17 (02) 193-199
  • 12 Heaf JG, Hansen A, Laier GH. Hypertensive nephropathy is associated with an increased risk of myeloma, skin, and renal cancer. J Clin Hypertens (Greenwich) 2019; 21 (06) 786-791
  • 13 Christiansen CF, Onega T, Sværke C. et al. Risk and prognosis of cancer in patients with nephrotic syndrome. Am J Med 2014; 127 (09) 871-7.e1
  • 14 Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis. Kidney Int 2003; 63 (02) 716-721
  • 15 Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19 (01) 135-140
  • 16 Wang D, Fan G, Liu X, Wu S, Zhai Z. Renal insufficiency and short-term outcomes of acute pulmonary embolism: a systemic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1025-1034
  • 17 Pedersen AB, Vandenbroucke J, Horváth-Puhó E, Sørensen HT. Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis. J Thromb Haemost 2017; 15 (12) 2325-2332
  • 18 Sørensen GV, Erichsen R, Svaerke C, Farkas DK, Sørensen HT. Risk of cancer in patients with inflammatory bowel disease and venous thromboembolism: a nationwide cohort study. Inflamm Bowel Dis 2012; 18 (10) 1859-1863
  • 19 Valerio L, Mavromanoli AC, Barco S. et al; FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J 2022; 43 (36) 3387-3398
  • 20 Robertson L, Yeoh SE, Broderick C, Stansby G, Agarwal R. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database Syst Rev 2018; 11 (11) CD010837
  • 21 Patel SS, Tao D, McMurry HS, Shatzel JJ. Screening for occult cancer after unprovoked venous thromboembolism: assessing the current literature and future directions. Eur J Haematol 2023; 110 (01) 24-31
  • 22 Schulman S, Konstantinides S, Hu Y, Tang LV. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing: observations on NICE guideline [NG158]. Thromb Haemost 2020; 120 (08) 1143-1146
  • 23 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603